IL141452A0 - Methods and compositions for modulating the interaction between the apj receptor and the hiv virus - Google Patents

Methods and compositions for modulating the interaction between the apj receptor and the hiv virus

Info

Publication number
IL141452A0
IL141452A0 IL14145299A IL14145299A IL141452A0 IL 141452 A0 IL141452 A0 IL 141452A0 IL 14145299 A IL14145299 A IL 14145299A IL 14145299 A IL14145299 A IL 14145299A IL 141452 A0 IL141452 A0 IL 141452A0
Authority
IL
Israel
Prior art keywords
modulating
interaction
compositions
methods
hiv virus
Prior art date
Application number
IL14145299A
Other languages
English (en)
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of IL141452A0 publication Critical patent/IL141452A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7158—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for chemokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Plant Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Chemical & Material Sciences (AREA)
  • AIDS & HIV (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IL14145299A 1998-09-08 1999-09-07 Methods and compositions for modulating the interaction between the apj receptor and the hiv virus IL141452A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/149,045 US6475718B2 (en) 1998-09-08 1998-09-08 Methods and compositions for modulating the interaction between the APJ receptor and the HIV virus
PCT/EP1999/006553 WO2000014220A1 (en) 1998-09-08 1999-09-07 Methods and compositions for modulating the interaction between the apj receptor and the hiv virus

Publications (1)

Publication Number Publication Date
IL141452A0 true IL141452A0 (en) 2002-03-10

Family

ID=22528559

Family Applications (1)

Application Number Title Priority Date Filing Date
IL14145299A IL141452A0 (en) 1998-09-08 1999-09-07 Methods and compositions for modulating the interaction between the apj receptor and the hiv virus

Country Status (14)

Country Link
US (5) US6475718B2 (ja)
EP (1) EP1109906A1 (ja)
JP (1) JP2002532061A (ja)
KR (1) KR20020013467A (ja)
AU (1) AU767484B2 (ja)
BR (1) BR9913635A (ja)
CA (1) CA2341782A1 (ja)
HU (1) HUP0103768A3 (ja)
IL (1) IL141452A0 (ja)
NO (1) NO20011162D0 (ja)
PL (1) PL346564A1 (ja)
RU (1) RU2225721C2 (ja)
SK (1) SK3082001A3 (ja)
WO (1) WO2000014220A1 (ja)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1419563A (zh) * 2000-03-23 2003-05-21 武田药品工业株式会社 肽衍生物
AU2001264937A1 (en) * 2000-05-23 2001-12-03 Genaissance Pharmaceuticals, Inc. Haplotypes of the agtrl1 gene
US20060045880A1 (en) * 2004-08-23 2006-03-02 Krieg Paul A Methods for modulating angiogenesis and apoptosis with apelin compositions
NZ623716A (en) 2008-04-11 2016-04-29 Chugai Pharmaceutical Co Ltd Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
TWI440469B (zh) 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
CA2819356C (en) * 2010-11-30 2023-01-24 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
EP3604330A1 (en) 2011-02-25 2020-02-05 Chugai Seiyaku Kabushiki Kaisha Fcgammariib-specific fc antibody
RS57397B8 (sr) 2011-06-10 2020-01-31 Univ Oregon Health & Science Cmv glikoproteini i rekombinantni vektori
US20150050269A1 (en) 2011-09-30 2015-02-19 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule promoting disappearance of antigens having plurality of biological activities
TW201326209A (zh) 2011-09-30 2013-07-01 Chugai Pharmaceutical Co Ltd 具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子
KR102126593B1 (ko) * 2011-12-16 2020-06-24 카아길, 인코포레이팃드 환경친화적으로 개선된 제빙제 조성물
AU2014236451B2 (en) 2013-03-14 2018-08-09 Regeneron Pharmaceuticals, Inc. Apelin fusion proteins and uses thereof
BR112016011401A2 (pt) 2013-11-20 2017-09-26 Regeneron Pharma moduladores de aplnr e utilizações dos mesmos
TWI617580B (zh) 2014-12-19 2018-03-11 中外製藥股份有限公司 抗ｃ５抗體及使用方法
KR20180054923A (ko) 2014-12-19 2018-05-24 추가이 세이야쿠 가부시키가이샤 항-마이오스타틴 항체, 변이체 Fc 영역을 함유하는 폴리펩타이드, 및 사용 방법
KR20170110129A (ko) 2015-02-05 2017-10-10 추가이 세이야쿠 가부시키가이샤 이온 농도 의존적 항원 결합 도메인을 포함하는 항체, Fc 영역 개변체, IL-8에 결합하는 항체, 및 그들의 사용
TW202339800A (zh) 2015-02-27 2023-10-16 日商中外製藥股份有限公司 Il-6受體抗體用於製備醫藥組成物的用途
US11359009B2 (en) 2015-12-25 2022-06-14 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies and methods of use
CA3026050A1 (en) 2016-08-05 2018-02-08 Chugai Seiyaku Kabushiki Kaisha Composition for prophylaxis or treatment of il-8 related diseases
JP7191833B2 (ja) 2017-01-30 2022-12-19 中外製薬株式会社 抗スクレロスチン抗体およびその使用
JP7185884B2 (ja) 2017-05-02 2022-12-08 国立研究開発法人国立精神・神経医療研究センター Ｉｌ－６及び好中球の関連する疾患の治療効果の予測及び判定方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0975749A2 (en) 1996-05-28 2000-02-02 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Cc chemokine receptor 5, antibodies thereto, transgenic animals
US6528625B1 (en) * 1996-10-28 2003-03-04 Millennium Pharmaceuticals, Inc. Anti-CCR5 antibodies and kits comprising same

Also Published As

Publication number Publication date
EP1109906A1 (en) 2001-06-27
US20020062488A1 (en) 2002-05-23
RU2225721C2 (ru) 2004-03-20
WO2000014220A1 (en) 2000-03-16
BR9913635A (pt) 2001-05-22
HUP0103768A2 (hu) 2002-02-28
CA2341782A1 (en) 2000-03-16
AU767484B2 (en) 2003-11-13
US20030008376A1 (en) 2003-01-09
AU5973799A (en) 2000-03-27
US6475718B2 (en) 2002-11-05
US20030008391A1 (en) 2003-01-09
SK3082001A3 (en) 2001-09-11
US20030008279A1 (en) 2003-01-09
NO20011162L (no) 2001-03-07
KR20020013467A (ko) 2002-02-20
US20030003447A1 (en) 2003-01-02
PL346564A1 (en) 2002-02-11
JP2002532061A (ja) 2002-10-02
HUP0103768A3 (en) 2004-07-28
NO20011162D0 (no) 2001-03-07

Similar Documents

Publication Publication Date Title
IL141452A0 (en) Methods and compositions for modulating the interaction between the apj receptor and the hiv virus
GC0000117A (en) Ccr5 modulators.
GB2337755B (en) Virus vaccine
HUP0103908A3 (en) Novel infulenza virus vaccine composition
ZA200004956B (en) Vaccine composition.
IL136938A0 (en) 11β-HALOGEN-7α-SUBSTITUTED ESTRATRIENES, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AND METHODS FOR THE PREPARATION THEREOF
IL138280A0 (en) 20-KETO-11β-ARYLSTERIODS, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AND METHODS FOR THE PREPARATION THEREOF
HUP0001539A3 (en) 2-(1-iminoethylamino)ethyl-homocysteine, process for its preparation and pharmaceutical compositions containing the same
SG71879A1 (en) Controlled release compositions
CY2408B1 (en) Paroxetine controlled release compositions.
SG71789A1 (en) Controlled release compositions
ZA976815B (en) Vaccine composition.
IL145891A0 (en) Methods and compositions for modulating an immune response
GB9826069D0 (en) HIV vaccine
AU2106001A (en) Methods and compositions for screening for angiogenesis modulating compounds
IL138207A0 (en) Methods and devices for modulating the immune response
PL343432A1 (en) Methods and devices for modulating the immune response
GB9809666D0 (en) Modified viruses
AU7471098A (en) Recombinant influenza viruses expressing tumor-associated antigens as antitum or agents
GB9823835D0 (en) Component for vaccine
EP1088067A4 (en) TECHNIQUES AND COMPOSITIONS FOR MODULATING SPERMATOGENESIS
IL136119A0 (en) Flame resistant polyolefin compositions and methods for the preparation thereof
DE69940886D1 (en) Hiv impfstoff
GB9702990D0 (en) Virus vaccine
AUPP517298A0 (en) Wedge device